

Gene Transfer Technologies Market by Product (Instruments, Kits, Assays), Mode (Viral (Retrovirus, Adenovirus, AAV), Non-viral (Electroporation, Gene Gun)), Method (In-Vivo, In-vitro), Application, (Gene Therapy, Research) - Global Forecast to 2029

Market Report | 2025-01-23 | 525 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global gene transfer technologies market is projected to surpass USD 5.93 billion in 2029 from USD 3.73 billion in 2024, with a significant CAGR of 9.7%. Increasing demand for personalized medicines, along with advancements in cell and gene therapies, continues to grow and contribute to a rise in this market. In addition, the increased application of gene transfer technologies in vaccine development and cancer immunotherapy boosts the segmental growth.

"The viral vector gene transfer technologies segment accounted for the largest share in 2023."

On the basis of mode, the gene transfer technologies market is further segmented into viral vector and non-viral vector. The viral vector segment is retrovirus, adenovirus, adeno associated virus (AAV) and other virus vector. The viral vector segment dominated the market in 2023, owing to superior safety and efficacy profile, minimal immunogenicity and advancements in AAV engineering.

"By application, the therapeutic application segment accounted for the largest share in the gene transfer technologies market."

The application segment in the gene transfer technologies market is segmented into research application, therapeutic application and applications. The research application is segmented into drug discovery & development and other research application. Similarly the therapeutic application further divided into gene therapy, cell therapy, vaccines and other therapeutic application. The therapeutic application dominated the segment owing to advancements in gene transfer technologies, such as improved adeno-associated virus (AAV) & lentiviral vector and expanding application of gene therapy in cardiovascular, neurological and metabolic diseases.

"North America: the largest share of the gene transfer technologies market"

By region, the market is segment into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. North America dominated the gene transfer technologies market in 2023 and likely continue dominance during the forecast period.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Presence of dominant market players in gene transfer technologies companies in the region, strong base of gene transfer technologies manufacturers such as Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany) are some of the prominent factors accelerating market growth.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the gene transfer technologies market.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side- 70% and Demand Side 30%

-□By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%

-□By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Qiagen (Netherlands), Sartorius AG (Germany), Bio-Rad Laboratories Inc. (US), Revvity (US), Agilent Technologies, Inc. (US), Genscript (US), Bio-Techne (US), Lonza (Switzerland), Takara Bio, Inc. (Japan), Promega Corporation (US), Oxford Biomedica plc (UK) and MaxCyte (US)) are some of the major players operating in the gene transfer technologies market.

Research Coverage:

This research report categorizes the gene transfer technologies market product (instruments, consumables, reagents, kits & assays and other products), mode (viral vector and non viral vector), method (ex vivo, in vivo and in vitro), application (research, therapeutic and other application) end user (pharmaceutical & biotechnology companies, academic & research institutes and other end users) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the gene transfer technologies market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the gene transfer technologies market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the gene transfer technologies and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

-□Analysis of key drivers (Growing demand for personalized medicines and cell & gene therapies, Increased investments in gene therapy research, Expanding applications in vaccine development & cancer immunotherapy), restraints (High costs of gene transfer systems), opportunities (Advancements in gene editing technologies and nanotechnology, Integration with digital technologies such as AI and ML) and Challenges (Scalability of production).

-□Product Development/Innovation: Detailed insights on maintaining a comprehensive and innovative product portfolio offering for gene transfer technologies.

-□Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

-□Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the gene transfer technologies market

-□Competitive Assessment: Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), Qiagen (Netherlands), Sartorius AG (Germany) and among others in the market.

Table of Contents:

1□INTRODUCTION□48

1.1□STUDY OBJECTIVES□48

1.2□MARKET DEFINITION□48

1.3□STUDY SCOPE□49

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1.3.1	MARKETS COVERED AND REGIONAL SCOPE	49
1.3.2	INCLUSIONS & EXCLUSIONS	50
1.3.3	YEARS CONSIDERED	50
1.3.4	CURRENCY CONSIDERED	51
1.4	STAKEHOLDERS	51
2	RESEARCH METHODOLOGY	52
2.1	RESEARCH DATA	52
2.1.1	SECONDARY DATA	52
2.1.2	PRIMARY DATA	53
2.2	MARKET ESTIMATION METHODOLOGY	55
2.2.1	MARKET ESTIMATION	55
2.2.2	INSIGHTS FROM PRIMARY EXPERTS	57
2.2.3	TOP-DOWN APPROACH	58
2.3	MARKET GROWTH RATE PROJECTION	59
2.4	DATA TRIANGULATION	61
2.5	RESEARCH ASSUMPTIONS	61
2.6	RESEARCH LIMITATIONS	62
2.7	RISK ANALYSIS	63
3	EXECUTIVE SUMMARY	64
4	PREMIUM INSIGHTS	69
4.1	GENE DELIVERY TECHNOLOGIES MARKET OVERVIEW	69
4.2	NORTH AMERICA: GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION (2023)	70
4.3	GENE DELIVERY TECHNOLOGIES MARKET SHARE, BY MODE, 2024 VS. 2029	70
4.4	GENE DELIVERY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	71
	?	
5	MARKET OVERVIEW	72
5.1	INTRODUCTION	72
5.2	MARKET DYNAMICS	72
5.2.1	DRIVERS	73
5.2.1.1	Growing demand for personalized medicine and cell & gene therapies	73
5.2.1.2	Increased investments in gene therapy research	74
5.2.1.3	Expanding applications in vaccine development & cancer immunotherapy	75
5.2.2	RESTRAINTS	75
5.2.2.1	High costs of gene delivery systems	75
5.2.3	OPPORTUNITIES	76
5.2.3.1	Advancements in gene editing technologies & nanotechnology	76
5.2.3.2	Integration with digital technologies such as AI & ML	76
5.2.4	CHALLENGES	77
5.2.4.1	Scalability of production	77
5.3	ECOSYSTEM ANALYSIS	78
5.3.1	PRODUCT PROVIDERS	78
5.3.2	END USERS	79
5.3.3	REGULATORY BODIES	79
5.4	TECHNOLOGY ANALYSIS	80
5.4.1	KEY TECHNOLOGIES	80
5.4.1.1	Microinjection	80
5.4.1.2	Electroporation	80

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.4.1.3	Sonoporation	81
5.4.2	COMPLEMENTARY TECHNOLOGIES	81
5.4.2.1	Gene editing technologies	81
5.4.2.2	Bioinformatics and computational tools	81
5.4.3	ADJACENT TECHNOLOGIES	82
5.4.3.1	Nanotechnology and nano-carriers	82
5.5	PRICING ANALYSIS	82
5.5.1	AVERAGE SELLING PRICE TREND OF REAGENTS/CONSUMABLES, BY KEY PLAYER	82
5.5.2	AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION	84
5.6	VALUE CHAIN ANALYSIS	84
5.7	SUPPLY CHAIN ANALYSIS	86
5.8	PATENT ANALYSIS	87
5.9	TRADE ANALYSIS	89
5.9.1	IMPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS OR ELECTROPHORESIS (HS CODE: 854330)	89
5.9.2	EXPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS OR ELECTROPHORESIS (HS CODE: 854330)	90
5.10	KEY CONFERENCES AND EVENTS, 2024-2025	90
5.11	REGULATORY LANDSCAPE	91
5.11.1	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	91
5.11.2	REGULATORY FRAMEWORK	93
5.11.2.1	North America	93
5.11.2.2	Europe	94
5.11.2.3	Asia Pacific	94
5.11.2.4	Rest of the World	95
5.12	PORTER'S FIVE FORCES ANALYSIS	96
5.12.1	THREAT OF NEW ENTRANTS	97
5.12.2	THREAT OF SUBSTITUTES	97
5.12.3	BARGAINING POWER OF BUYERS	97
5.12.4	BARGAINING POWER OF SUPPLIERS	97
5.12.5	INTENSITY OF COMPETITIVE RIVALRY	97
5.13	KEY STAKEHOLDERS AND BUYING CRITERIA	97
5.13.1	KEY STAKEHOLDERS	98
5.13.2	BUYING CRITERIA	99
5.14	INVESTMENT AND FUNDING SCENARIO	100
5.15	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	101
5.16	IMPACT OF AI/GEN AI ON GENE DELIVERY TECHNOLOGIES MARKET	102
6	GENE DELIVERY TECHNOLOGIES MARKET, BY PRODUCT	104
6.1	INTRODUCTION	105
6.2	REAGENTS, KITS, AND ASSAYS	105
6.2.1	INCREASING DEMAND FOR TRANSFECTION AND GENE EDITING TOOLS TO DRIVE MARKET GROWTH	105
6.3	CONSUMABLES	109
6.3.1	RISING R&D ACTIVITY TO SUPPORT DEMAND GROWTH	109
6.4	INSTRUMENTS	112
6.4.1	INCREASING ADOPTION OF ELECTROPORATION DEVICES TO DRIVE MARKET	112
6.5	OTHER PRODUCTS	116
7	GENE DELIVERY TECHNOLOGIES MARKET, BY MODE	119

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.1	INTRODUCTION	120
7.2	VIRAL VECTORS	120
7.2.1	RETROVIRUSES	124
7.2.1.1	Lentiviruses	127
7.2.1.1.1	Rising disease incidence to drive market	127
7.2.1.2	Other retroviruses	130
7.2.2	ADENOVIRUSES	133
7.2.2.1	Expansion of vaccination programs to propel market growth	133
7.2.3	ADENO-ASSOCIATED VIRUSES	137
7.2.3.1	Low immunogenicity of AAV vectors to support adoption	137
7.2.4	OTHER VIRAL VECTORS	140
7.3	NON-VIRAL VECTORS	143
7.3.1	CHEMICAL METHODS	147
7.3.2	LIPOSOME-MEDIATED	151
7.3.2.1	High efficiency and compatibility to drive market	151
7.3.3	CALCIUM PHOSPHATE	154
7.3.3.1	Increasing R&D in cell-based therapies to propel market growth	154
7.3.4	DEAE-DEXTRAN	158
7.3.4.1	Simplicity and cost-effectiveness to support adoption	158
7.3.5	CATIONIC POLYMERS	161
7.3.5.1	Advancements in cationic polymer technology to drive market	161
7.3.6	OTHER CHEMICAL METHODS	165
7.4	PHYSICAL METHODS	168
7.4.1	ELECTROPORATION	172
7.4.1.1	Rising demand for effective cell transfection technologies to drive market	172
7.4.2	MICROINJECTION	175
7.4.2.1	High accuracy and control and potential for tailored delivery to drive market	175
7.4.3	GENE GUNS	179
7.4.3.1	High efficiency of gene guns in transfecting various cell types to drive market	179
7.4.4	OTHER PHYSICAL METHODS	182
8	GENE DELIVERY TECHNOLOGIES MARKET, BY METHOD	186
8.1	INTRODUCTION	187
8.2	IN VIVO	187
8.2.1	EMERGENCE OF MRNA-BASED VACCINES TO PROPEL IN VIVO GENE DELIVERY APPLICATIONS	187
8.3	EX VIVO	191
8.3.1	SUCCESSFUL COMMERCIALIZATION OF CAR T-CELL THERAPIES TO DRIVE THE EX VIVO GENE DELIVERY MARKET	191
8.4	IN VITRO	194
8.4.1	DATABASES MAJORLY CONTRIBUTE TO STORING GENE DELIVERY TECHNOLOGIES AND INTEGRATING OTHER OMICS DATABASES.	194
9	GENE DELIVERY TECHNOLOGIES MARKET, BY APPLICATION	198
9.1	INTRODUCTION	199
9.2	THERAPEUTIC APPLICATIONS	199
9.2.1	GENE THERAPY	203
9.2.1.1	Increasing demand for personalized medicine to support market growth	203
9.2.2	CELL THERAPY	206
9.2.2.1	Rising government funding to propel market growth	206
9.2.3	VACCINES	209

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.2.3.1 Rising prevalence of infectious diseases to drive market growth 209
- 9.2.4 OTHER THERAPEUTIC APPLICATIONS 213
- 9.3 RESEARCH APPLICATIONS 216
- 9.3.1 DRUG DISCOVERY & DEVELOPMENT 220
- 9.3.1.1 Increased funding for gene therapy research to drive market growth 220
- 9.3.1.2 Cancer 224
- 9.3.1.2.1 Rising investment in cancer research to drive market 224
- 9.3.2 INFECTIOUS DISEASES 228
- 9.3.2.1 Rising incidence of infectious disease to drive market growth 228
- 9.3.3 GENETIC & NEUROLOGICAL DISORDERS 231
- 9.3.3.1 Rising burden of disorders to drive market 231
- 9.3.4 AUTOIMMUNE DISEASES 235
- 9.3.4.1 Growing prevalence of autoimmune disorders to ensure demand for therapeutic solutions 235
- 9.3.5 OTHER DISEASES 238
- 9.3.6 OTHER RESEARCH APPLICATIONS 242
- 9.4 OTHER APPLICATIONS 245
- 10 GENE DELIVERY TECHNOLOGIES MARKET, BY END USER 249
- 10.1 INTRODUCTION 250
- 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 250
- 10.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO DOMINATE MARKET 250
- 10.3 ACADEMIC & RESEARCH INSTITUTES 254
- 10.3.1 INCREASING R&D AND GROWING FUNDING AND PARTNERSHIPS TO PROMOTE MARKET GROWTH 254
- 10.4 OTHER END USERS 257
- 11 GENE DELIVERY TECHNOLOGIES MARKET, BY REGION 261
- 11.1 INTRODUCTION 262
- 11.2 NORTH AMERICA 262
- 11.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 263
- 11.2.2 US 269
- 11.2.2.1 US to dominate North American market over forecast period 269
- 11.2.3 CANADA 274
- 11.2.3.1 Strong infrastructure and availability of funding for biomedical research to support market growth 274
- 11.3 EUROPE 279
- 11.3.1 EUROPE: MACROECONOMIC OUTLOOK 280
- 11.3.2 GERMANY 285
- 11.3.2.1 Germany to hold largest market share in Europe 285
- ?
- 11.3.3 UK 291
- 11.3.3.1 Increasing government funding to drive market growth 291
- 11.3.4 FRANCE 296
- 11.3.4.1 Rising support for genetic research to offer potential growth opportunities 296
- 11.3.5 ITALY 301
- 11.3.5.1 Rising R&D and support for gene delivery to drive market 301
- 11.3.6 SPAIN 306
- 11.3.6.1 Growing expansion of research centers to stimulate market 306
- 11.3.7 REST OF EUROPE 311
- 11.4 ASIA PACIFIC 316
- 11.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 316

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.4.2	CHINA	323
11.4.2.1	Increasing R&D expenditure to drive market growth	323
11.4.3	JAPAN	328
11.4.3.1	Rising research into precision medicine to support market growth	328
11.4.4	INDIA	334
11.4.4.1	Strong research base and rising FDI in pharma sector to support market growth	334
11.4.5	SOUTH KOREA	339
11.4.5.1	Alliances & investments in research to drive market	339
11.4.6	AUSTRALIA	344
11.4.6.1	Increasing focus on precision medicine to offer significant growth opportunities	344
11.4.7	REST OF ASIA PACIFIC	349
11.5	LATIN AMERICA	354
11.5.1	LATIN AMERICA: MACROECONOMIC OUTLOOK	354
11.5.2	BRAZIL	360
11.5.2.1	Brazil to hold largest market share in LATAM	360
11.5.3	MEXICO	365
11.5.3.1	Strong pharmaceutical industry and increased government support to augment market growth	365
11.5.4	REST OF LATIN AMERICA	370
11.6	MIDDLE EAST	375
11.6.1	MIDDLE EAST: MACROECONOMIC OUTLOOK	375
11.6.2	GCC COUNTRIES	381
11.6.2.1	Saudi Arabia	386
11.6.2.1.1	Increasing government investments in healthcare and growing pharmaceuticals industry to support market	386
11.6.2.2	UAE	392
11.6.2.2.1	Growing R&D expenditure and infrastructural development to drive market	392
11.6.2.3	Rest of GCC Countries	397
11.6.3	REST OF MIDDLE EAST	403
11.7	AFRICA	408
11.7.1	RIISING EMPHASIS ON GENE DELIVERY TECHNOLOGIES FOR THERAPEUTICS TO SUPPORT MARKET GROWTH	408
11.7.2	MACROECONOMIC OUTLOOK FOR AFRICA	409
12	COMPETITIVE LANDSCAPE	415
12.1	OVERVIEW	415
12.2	KEY PLAYER STRATEGIES/RIGHT TO WIN	415
12.2.1	OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GENE DELIVERY TECHNOLOGIES MARKET	415
12.3	REVENUE ANALYSIS	417
12.4	MARKET SHARE ANALYSIS	417
12.5	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	419
12.5.1	STARS	419
12.5.2	EMERGING LEADERS	419
12.5.3	PERVASIVE PLAYERS	420
12.5.4	PARTICIPANTS	420
12.5.5	COMPANY FOOTPRINT: KEY PLAYERS, 2023	421
12.5.5.1	Company footprint	421
12.5.5.2	Region footprint	421
12.5.5.3	Product footprint	422
12.5.5.4	Method footprint	423
12.5.5.5	Application footprint	424

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

12.5.5.6	End-user footprint	425
12.6	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	425
12.6.1	PROGRESSIVE COMPANIES	425
12.6.2	RESPONSIVE COMPANIES	425
12.6.3	DYNAMIC COMPANIES	426
12.6.4	STARTING BLOCKS	426
12.6.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023	427
12.7	COMPANY VALUATION & FINANCIAL METRICS	428
12.7.1	FINANCIAL METRICS	428
12.7.2	COMPANY VALUATION	428
12.8	BRAND/PRODUCT COMPARISON	429
12.9	COMPETITIVE SCENARIO	430
12.9.1	PRODUCT LAUNCHES	430
12.9.2	DEALS	431
12.9.3	EXPANSIONS	432
?		
13	COMPANY PROFILES	433
13.1	KEY PLAYERS	433
13.1.1	THERMO FISHER SCIENTIFIC INC.	433
13.1.1.1	Business overview	433
13.1.1.2	Products/Services/Solutions offered	434
13.1.1.3	Recent developments	441
13.1.1.3.1	Product launches	441
13.1.1.3.2	Expansions	441
13.1.1.4	MnM view	441
13.1.1.4.1	Key strengths	441
13.1.1.4.2	Strategic choices	442
13.1.1.4.3	Weaknesses and competitive threats	442
13.1.2	DANAHER CORPORATION	443
13.1.2.1	Business overview	443
13.1.2.2	Products/Services/Solutions offered	444
13.1.2.3	Recent developments	446
13.1.2.3.1	Product launches	446
13.1.2.3.2	Deals	447
13.1.2.3.3	Expansions	447
13.1.2.4	MnM view	447
13.1.2.4.1	Key strengths	447
13.1.2.4.2	Strategic choices	448
13.1.2.4.3	Weaknesses and competitive threats	448
13.1.3	MERCK KGAA	449
13.1.3.1	Business overview	449
13.1.3.2	Products/Services/Solutions offered	450
13.1.3.3	Recent developments	453
13.1.3.3.1	Deals	453
13.1.3.3.2	Expansions	454
13.1.3.4	MnM view	454
13.1.3.4.1	Key strengths	454

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.1.3.4.2 Strategic choices 454
- 13.1.3.4.3 Weaknesses and competitive threats 454
- 13.1.4 BIO-RAD LABORATORIES, INC. 455
 - 13.1.4.1 Business overview 455
 - 13.1.4.2 Products/Services/Solutions offered 456
- 13.1.5 AGILENT TECHNOLOGIES, INC. 458
 - 13.1.5.1 Business overview 458
 - 13.1.5.2 Products/Services/Solutions offered 459
 - 13.1.5.3 Recent developments 461
 - 13.1.5.3.1 Deals 461
- ?
- 13.1.6 REVVITY 462
 - 13.1.6.1 Business overview 462
 - 13.1.6.2 Products/Services/Solutions offered 463
 - 13.1.6.3 Recent developments 465
 - 13.1.6.3.1 Product launches 465
 - 13.1.6.3.2 Deals 465
- 13.1.7 QIAGEN 466
 - 13.1.7.1 Business overview 466
 - 13.1.7.2 Products/Services/Solutions offered 467
- 13.1.8 GENSCRIPT 469
 - 13.1.8.1 Business overview 469
 - 13.1.8.2 Products/Services/Solutions offered 470
 - 13.1.8.3 Recent developments 471
 - 13.1.8.3.1 Deals 471
- 13.1.9 TAKARA BIO INC. 472
 - 13.1.9.1 Business overview 472
 - 13.1.9.2 Products/Services/Solutions offered 473
 - 13.1.9.3 Recent developments 479
 - 13.1.9.3.1 Product launches 479
 - 13.1.9.3.2 Deals 479
- 13.1.10 PROMEGA CORPORATION 480
 - 13.1.10.1 Business overview 480
 - 13.1.10.2 Products/Services/Solutions offered 480
- 13.1.11 BIO-TECHNE 482
 - 13.1.11.1 Business overview 482
 - 13.1.11.2 Products/Services/Solutions offered 483
 - 13.1.11.3 Recent developments 485
 - 13.1.11.3.1 Product launches 485
- 13.1.12 LONZA 486
 - 13.1.12.1 Business overview 486
 - 13.1.12.2 Products/Services/Solutions offered 487
 - 13.1.12.3 Recent developments 489
 - 13.1.12.3.1 Product launches 489
 - 13.1.12.3.2 Deals 489
- 13.1.13 OXFORD BIOMEDICA PLC 490
 - 13.1.13.1 Business overview 490

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.1.13.2 Products/Services/Solutions offered 491
- 13.1.13.3 Recent developments 492
 - 13.1.13.3.1 Product launches 492
 - 13.1.13.3.2 Deals 492
 - 13.1.13.3.3 Other developments 493
- ?
- 13.1.14 SARTORIUS AG 494
 - 13.1.14.1 Business overview 494
 - 13.1.14.2 Products/Services/Solutions offered 495
 - 13.1.14.3 Recent developments 497
 - 13.1.14.3.1 Product launches 497
 - 13.1.14.3.2 Deals 497
- 13.1.15 MAXCYTE 498
 - 13.1.15.1 Business overview 498
 - 13.1.15.2 Products/Services/Solutions offered 499
 - 13.1.15.3 Recent developments 500
 - 13.1.15.3.1 Deals 500
- 13.2 OTHER PLAYERS 503
 - 13.2.1 CELL BIOLABS, INC. 503
 - 13.2.2 GENTARGET INC. 505
 - 13.2.3 ORIGENE TECHNOLOGIES, INC. 507
 - 13.2.4 ALTOGEN BIOSYSTEMS 508
 - 13.2.5 OZ BIOSCIENCES 510
 - 13.2.6 GENECOPOEIA, INC. 512
 - 13.2.7 CREATIVE BIOLABS 513
 - 13.2.8 SYN BIO TECHNOLOGIES LLC 513
 - 13.2.9 SYSTEM BIOSCIENCES, LLC 514
 - 13.2.10 VECTORBUILDER INC. 515
- 14 APPENDIX 517
 - 14.1 DISCUSSION GUIDE 517
 - 14.2 KNOWLEDGESTORE: MARKET SAND MARKETS' SUBSCRIPTION PORTAL 521
 - 14.3 CUSTOMIZATION OPTIONS 523
 - 14.4 RELATED REPORTS 523
 - 14.5 AUTHOR DETAILS 524

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Gene Transfer Technologies Market by Product (Instruments, Kits, Assays), Mode (Viral (Retrovirus, Adenovirus, AAV), Non-viral (Electroporation, Gene Gun)), Method (In-Vivo, In-vitro), Application, (Gene Therapy, Research) - Global Forecast to 2029

Market Report | 2025-01-23 | 525 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2026-06-09

Signature

A large, empty rectangular box intended for a signature.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com